CL2013001428A1 - Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c. - Google Patents

Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.

Info

Publication number
CL2013001428A1
CL2013001428A1 CL2013001428A CL2013001428A CL2013001428A1 CL 2013001428 A1 CL2013001428 A1 CL 2013001428A1 CL 2013001428 A CL2013001428 A CL 2013001428A CL 2013001428 A CL2013001428 A CL 2013001428A CL 2013001428 A1 CL2013001428 A1 CL 2013001428A1
Authority
CL
Chile
Prior art keywords
compound
hepatitis
hcv
virus
activity
Prior art date
Application number
CL2013001428A
Other languages
English (en)
Inventor
Elizabeth M Bacon
Jeromy J Cottel
Ashley Anne Katana
Darryl Kato
Evan S Krygowski
John O Lin
James Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Zheng-Yu Yang
Sheila Zippel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001428(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2013001428A1 publication Critical patent/CL2013001428A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
CL2013001428A 2011-11-16 2013-05-17 Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c. CL2013001428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161560654P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
CL2013001428A1 true CL2013001428A1 (es) 2014-06-27

Family

ID=47324426

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001428A CL2013001428A1 (es) 2011-11-16 2013-05-17 Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.

Country Status (37)

Country Link
US (14) US20130164260A1 (es)
EP (4) EP3778606A3 (es)
JP (5) JP6082749B2 (es)
KR (5) KR101890400B1 (es)
CN (2) CN103328480B (es)
AP (1) AP2013006877A0 (es)
AU (1) AU2012318253B8 (es)
BR (1) BR112013012091A2 (es)
CA (2) CA2815082C (es)
CL (1) CL2013001428A1 (es)
CO (1) CO6791562A2 (es)
CR (1) CR20130231A (es)
CY (2) CY1116987T1 (es)
DK (2) DK2635588T3 (es)
EA (4) EA202190619A1 (es)
EC (2) ECSP13012790A (es)
ES (3) ES2687291T3 (es)
HK (1) HK1188989A1 (es)
HR (2) HRP20150725T1 (es)
HU (2) HUE027733T2 (es)
IL (5) IL226345A (es)
LT (1) LT2907816T (es)
MA (1) MA34727B1 (es)
MD (2) MD4403C1 (es)
ME (1) ME02196B (es)
MX (3) MX346729B (es)
MY (1) MY173045A (es)
PE (2) PE20141163A1 (es)
PH (1) PH12015502839B1 (es)
PL (3) PL3431477T3 (es)
PT (3) PT2635588E (es)
RS (2) RS54207B1 (es)
SG (1) SG10201700947UA (es)
SI (3) SI2907816T1 (es)
SM (1) SMT201500197B (es)
UA (2) UA110354C2 (es)
WO (1) WO2013075029A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
TWI640526B (zh) 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
AU2012283609B2 (en) 2011-07-09 2016-09-29 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis C virus inhibitors
MX354958B (es) 2011-09-16 2018-03-27 Gilead Pharmasset Llc Metodos para el tratamiento de vhc.
ME02196B (me) * 2011-11-16 2016-02-20 Gilead Pharmasset Llc Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
JP5614568B1 (ja) 2013-02-07 2014-10-29 保土谷化学工業株式会社 ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子
US20140343008A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatment
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
EP3087086B1 (en) 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
CN106008552B (zh) * 2015-03-01 2020-08-21 南京圣和药业股份有限公司 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
CN105801553B (zh) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 一种苯并色烯衍生物的制备方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
ES2926579T3 (es) 2016-05-05 2022-10-27 Laurus Labs Ltd Proceso para la preparación de compuestos intermedios útiles en la preparación de inhibidores del virus de la Hepatitis C (VHC)
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
JP6770098B2 (ja) 2016-05-27 2020-10-14 ギリアード サイエンシーズ， インコーポレイテッド Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN107674063B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 Gs5816中间体及制备方法和应用
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
CN107655986B (zh) * 2017-09-08 2020-11-03 安徽一灵药业有限公司 一种维帕他韦有关物质的检测方法
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN108276421B (zh) * 2018-02-13 2019-08-06 浙江永太药业有限公司 一种维帕他韦的合成方法
US11865108B2 (en) 2019-10-18 2024-01-09 Wockhardt Limited Nitrogen containing bicyclic compounds
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN110981879B (zh) * 2019-12-09 2021-03-05 南通常佑药业科技有限公司 一种制备ns5a抑制剂-维帕他韦的方法
CN113072615B (zh) * 2021-03-24 2023-01-10 上海法默生物科技有限公司 一种维帕他韦中间体的制备方法
CN117460734A (zh) * 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP1625154B1 (en) 2003-05-09 2014-01-08 Boehringer Ingelheim International GmbH Hepatitis c virus ns5b polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
ATE516293T1 (de) 2004-07-16 2011-07-15 Gilead Sciences Inc Antivirale verbindungen
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI442947B (zh) 2006-12-07 2014-07-01 Daiichi Sankyo Co Ltd 安定性經改善之薄膜塗覆製劑
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20100126352A (ko) * 2008-02-11 2010-12-01 퀄컴 엠이엠스 테크놀로지스, 인크. 간섭계 변조기의 측정 및 평가 방법
PT2250163E (pt) 2008-02-12 2012-06-01 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2242752E (pt) 2008-02-13 2012-10-29 Bristol Myers Squibb Co Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065681A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MY160130A (en) 2009-02-27 2017-02-28 Enanta Pharm Inc Hepatitis c virus inhibitors
WO2010111534A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
AP3622A (en) * 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5795316B2 (ja) * 2009-09-04 2015-10-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド 化合物
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104341401B (zh) * 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2785488A1 (en) * 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
TWI640526B (zh) 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
ME02196B (me) 2011-11-16 2016-02-20 Gilead Pharmasset Llc Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
EP2907505A3 (en) 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Also Published As

Publication number Publication date
CO6791562A2 (es) 2013-11-14
JP2016199593A (ja) 2016-12-01
EP3778606A2 (en) 2021-02-17
US20130156732A1 (en) 2013-06-20
NZ737924A (en) 2019-06-28
US20140309432A1 (en) 2014-10-16
NZ610525A (en) 2017-05-26
CN103328480A (zh) 2013-09-25
HRP20150725T1 (hr) 2015-08-14
EA201591244A1 (ru) 2016-02-29
KR101890400B1 (ko) 2018-08-21
IL244122A0 (en) 2016-04-21
MX346729B (es) 2017-03-30
HUE027733T2 (en) 2016-10-28
MD20150091A2 (ro) 2016-02-29
AU2012318253B2 (en) 2015-08-06
EP3778606A3 (en) 2021-03-03
MX2020010330A (es) 2020-10-22
JP2021001230A (ja) 2021-01-07
US20140112885A1 (en) 2014-04-24
US20180244683A1 (en) 2018-08-30
EA023644B1 (ru) 2016-06-30
HK1188989A1 (en) 2014-05-23
EA037883B1 (ru) 2021-05-31
EP3431477A1 (en) 2019-01-23
MD4403B1 (ro) 2016-02-29
SMT201500197B (it) 2015-09-07
WO2013075029A1 (en) 2013-05-23
PT2907816T (pt) 2018-10-18
EP2635588B1 (en) 2015-06-10
PT2635588E (pt) 2015-09-14
PH12015502839B1 (en) 2020-10-30
EA201890333A1 (ru) 2018-10-31
BR112013012091A2 (pt) 2019-09-10
KR20190121406A (ko) 2019-10-25
IL226345A (en) 2016-03-31
HRP20181384T1 (hr) 2018-12-28
IL252345B (en) 2022-01-01
ECSP18048718A (es) 2018-07-31
US20210053981A1 (en) 2021-02-25
NZ752834A (en) 2021-01-29
MD4403C1 (ro) 2016-09-30
IL252345A0 (en) 2017-07-31
KR20210043734A (ko) 2021-04-21
ES2843023T3 (es) 2021-07-15
HUE039966T2 (hu) 2019-02-28
MA34727B1 (fr) 2013-12-03
PH12015502839A1 (en) 2019-05-15
EA201390576A1 (ru) 2013-11-29
MX361735B (es) 2018-12-14
KR102241651B1 (ko) 2021-04-20
UA119437C2 (uk) 2019-06-25
JP6082749B2 (ja) 2017-02-15
IL244124A0 (en) 2016-04-21
US8921341B2 (en) 2014-12-30
AU2012318253A1 (en) 2013-05-30
RS54207B1 (en) 2015-12-31
EP2907816B1 (en) 2018-06-13
PE20141163A1 (es) 2014-09-21
SI2635588T1 (sl) 2015-10-30
SI2907816T1 (sl) 2018-10-30
IL226345A0 (en) 2013-07-31
JP2019206597A (ja) 2019-12-05
US20190276468A1 (en) 2019-09-12
UA110354C2 (uk) 2015-12-25
JP2015512860A (ja) 2015-04-30
US20130177530A1 (en) 2013-07-11
AP2013006877A0 (en) 2013-05-31
EA202190619A1 (ru) 2021-09-30
AU2012318253B8 (en) 2015-08-13
US9868745B2 (en) 2018-01-16
MD20130029A2 (en) 2013-09-30
KR102036469B1 (ko) 2019-10-24
PE20171444A1 (es) 2017-09-29
CA2815082C (en) 2015-07-07
JP2018024705A (ja) 2018-02-15
US9809600B2 (en) 2017-11-07
EA030941B1 (ru) 2018-10-31
ME02196B (me) 2016-02-20
US20200071337A1 (en) 2020-03-05
US20170145027A1 (en) 2017-05-25
CR20130231A (es) 2013-09-19
KR20200117043A (ko) 2020-10-13
SG10201700947UA (en) 2017-03-30
PL3431477T3 (pl) 2021-04-06
DK2907816T3 (en) 2018-09-24
US10807990B2 (en) 2020-10-20
US8575135B2 (en) 2013-11-05
SI3431477T1 (sl) 2021-01-29
US20180186806A1 (en) 2018-07-05
MD4521C1 (ro) 2018-05-31
PL2907816T3 (pl) 2019-03-29
MX2013005575A (es) 2013-09-05
CN103328480B (zh) 2016-05-25
LT2907816T (lt) 2018-09-10
CA2884712A1 (en) 2013-05-23
RS57638B1 (sr) 2018-11-30
ES2544107T3 (es) 2015-08-27
US20150299213A1 (en) 2015-10-22
IL244123A0 (en) 2016-04-21
CN105837584A (zh) 2016-08-10
US20160083394A1 (en) 2016-03-24
EP2907816A1 (en) 2015-08-19
ECSP13012790A (es) 2013-10-31
CA2815082A1 (en) 2013-05-23
KR20180095119A (ko) 2018-08-24
US20130164260A1 (en) 2013-06-27
CY1121225T1 (el) 2020-05-29
MD4521B1 (ro) 2017-10-31
CY1116987T1 (el) 2017-04-05
US9221833B2 (en) 2015-12-29
CN105837584B (zh) 2018-07-13
EP2635588A1 (en) 2013-09-11
PT3431477T (pt) 2020-12-15
AU2012318253A8 (en) 2015-08-13
NZ720856A (en) 2017-12-22
MY173045A (en) 2019-12-20
US8940718B2 (en) 2015-01-27
US9051340B2 (en) 2015-06-09
EP3431477B1 (en) 2020-10-14
DK2635588T3 (en) 2015-09-07
PL2635588T3 (pl) 2015-10-30
ES2687291T3 (es) 2018-10-24
KR20140096239A (ko) 2014-08-05
US20150141326A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
SMT201600470B (it) Inibitori del virus dell'epatite c
CL2013000727A1 (es) Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014000778A1 (es) Metodo de tratamiento para hcv que comprende al menos dos agentes antivirales de accion directa (daas), que no incluye interferon o ribavirina.
CL2014003168A1 (es) Compuestos derivados de tetrahidrofurano o tetrahidrotiofeno teniendo un resto d-aminoacido; composicion farmaceutica que los comprende, util para el tratamiento de un huesped infectado con el virus de la hepatitis c.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
SMT201700029B (it) Inibitori del virus dell'epatite c
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
EP2769973A4 (en) INGENANE TYPE DITERPENE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIOUS DISEASES CONTAINING THE SAME
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물